EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma

International Journal of Radiation Oncology Biology Physics

Volumn 55, Issue 3, 2003, Pages 713-723

  Solomon, Benjamin ^a,b   Hagekyriakou, Jim ^a   Trivett, Melanie K ^a   Stacker, Steven A ^c   McArthur, Grant A ^a,b   Cullinane, Carleen ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

"Iressa"; Combination treatment; EGFR; Radiation; ZD1839

Indexed keywords

CELLS; ENZYME INHIBITION; PROTEINS; RNA; TUMORS;

ANTITUMOR EFFECTS;

IONIZING RADIATION;

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; PRIORITY JOURNAL; RADIATION DOSE; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR VASCULARIZATION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOTHELIAL GROWTH FACTORS; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MICE; MICE, NUDE; PHOSPHORYLATION; QUINAZOLINES; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0347928791     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)04357-2     Document Type: Article

References (57)

1. Salomon D.S., Brandt R., Ciardiello F., et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol/Hematol. 19:1995;183-232.
2. Rusch V., Baselga J., Cordon-Cardo C., et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 53:1993;2379-2385.
3. Nicholson R.I., Gee J.M., Harper M.E. EGFR and cancer prognosis. Eur J Cancer. 37:2001;S9-S15.
4. Woodburn J.R. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther. 82:1999;241-250.
5. Magne N., Pivot X., Bensadoun R.J., et al. The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy. Eur J Cancer. 37:2001;2169-2177.
6. Barker F.G. 2nd, Simmons M.L., Chang S.M., et al. EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 51:2001;410-418.
7. Pillai M.R., Jayaprakash P.G., Nair M.K. Tumour-proliferative fraction and growth factor expression as markers of tumour response to radiotherapy in cancer of the uterine cervix. J Cancer Res Clin Oncol. 124:1998;456-461.
8. Akimoto T., Hunter N.R., Buchmiller L., et al. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res. 5:1999;2884-2890.
9. Sheridan M.T., O'Dwyer T., Seymour C.B., et al. Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat Oncol Investig. 5:1997;180-186.
10. Miyaguchi M., Takeuchi T., Morimoto K., et al. Correlation of epidermal growth factor receptor and radiosensitivity in human maxillary carcinoma cell lines. Acta Otolaryngol. 118:1998;428-431.
11. Dent P., Reardon D.B., Park J.S., et al. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation, and protection from radiation-induced cell death. Mol Biol Cell. 10:1999;2493-2506.
12. Hagan M., Wang L., Hanley J.R., et al. Ionizing radiation-induced mitogen-activated protein (MAP) kinase activation in DU145 prostate carcinoma cells MAP kinase inhibition enhances radiation-induced cell killing and G2/M-phase arrest . Radiat Res. 153:2000;371-383.
13. Reardon D.B., Contessa J.N., Mikkelsen R.B., et al. Dominant negative EGFR-CD533 and inhibition of MAPK modify JNK1 activation and enhance radiation toxicity of human mammary carcinoma cells. Oncogene. 18:1999;4756-4766.
14. Baselga J., Averbuch S.D. ZD1839 ('Iressa') as an anticancer agent. Drugs. 60:(Suppl. 1):2000;33-40.
15. Sirotnak F.M., Zakowski M.F., Miller V.A., et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res. 6:2000;4885-4892.
16. Ciardiello F., Caputo R., Bianco R., et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res. 6:2000;2053-2063.
17. Ranson M., Hammond L.A., Ferry D., et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors Results of a phase I trial . J Clin Oncol. 20:2002;2240-2250.
18. Taupin D., Wu D.C., Jeon W.K., et al. The trefoil gene family are coordinately expressed immediate-early genes EGF receptor- and MAP kinase-dependent interregulation . J Clin Invest. 103:1999;R31-R38.
19. Mason K.A., Kishi K., Hunter N., et al. Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo. Clin Cancer Res. 5:1999;4191-4198.
20. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 344:2001;1031-1037.
21. Joensuu H., Roberts P.J., Sarlomo-Rikala M., et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 344:2001;1052-1056.
22. Lin C.R., Chen W.S., Kruiger W., et al. Expression cloning of human EGF receptor complementary DNA Gene amplification and three related messenger RNA products in A431 cells . Science. 224:1984;843-848.
23. Ullrich A., Coussens L., Hayflick J.S., et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature. 309:1984;418-425.
24. Merlino G.T., Xu Y.H., Ishii S., et al. Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells. Science. 224:1984;417-419.
25. Milas L., Mason K., Hunter N., et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res. 6:2000;701-708.
26. Saleh M.N., Raisch K.P., Stackhouse M.A., et al. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm. 14:1999;451-463.
27. Huang S.M., Harari P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis . Clin Cancer Res. 6:2000;2166-2174.
28. Fan Z., Masui H., Altas I., et al. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 53:1993;4322-4328.
29. Bier H., Hoffmann T., Haas I., et al. Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother. 46:1998;167-173.
30. Gille J., Swerlick R.A., Caughman S.W. Transforming growth factor-alpha-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation. Embo J. 16:1997;750-759.
31. Goldman C.K., Kim J., Wong W.L., et al. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells A model of glioblastoma multiforme pathophysiology . Mol Biol Cell. 4:1993;121-133.
32. Petit A.M., Rak J., Hung M.C., et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo Angiogenic implications for signal transduction therapy of solid tumors . Am J Pathol. 151:1997;1523-1530.
33. Bruns C.J., Harbison M.T., Davis D.W., et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res. 6:2000;1936-1948.
34. Perrotte P., Matsumoto T., Inoue K., et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res. 5:1999;257-265.
35. Ciardiello F., Caputo R., Bianco R., et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res. 7:2001;1459-1465.
36. Kerbel R.S., Viloria-Petit A., Klement G., et al. 'Accidental' anti-angiogenic drugs; anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer. 36:2000;1248-1257.
37. Hirata A., Ogawa S., Kometani T., et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res. 62:2002;2554-2560.
38. Huang S.-M., Li J., Armstrong E.A., et al. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res. 62:2002;4300-4306.
39. Geng L., Donnelly E., McMahon G., et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res. 61:2001;2413-2419.
40. Lee C.G., Heijn M., di Tomaso E., et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60:2000;5565-5570.
41. Gorski D.H., Beckett M.A., Jaskowiak N.T., et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59:1999;3374-3378.
42. Ning S., Laird D., Cherrington J.M., et al. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res. 157:2002;45-51.
43. Murata R., Nishimura Y., Hiraoka M. An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int J Radiat Oncol Biol Phys. 37:1997;1107-1113.
44. Hansen-Algenstaedt N., Stoll B.R., Padera T.P., et al. Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy. Cancer Res. 60:2000;4556-4560.
45. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy A new paradigm for combination therapy . Nat Med. 7:2001;987-989.
46. Gray L.H., Conger A.D., Ebert M., Hornsey S., Scott O.C. Concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 26:1953;638-648.
47. Williams K.J., Telfer B.A., Stratford I.J., et al. ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer. 86:2002;1157-1161.
48. Schmidt-Ullrich R.K., Mikkelsen R.B., Dent P., et al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene. 15:1997;1191-1197.
49. Withers H.R., Taylor J.M., Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 27:1988;131-146.
50. Durand R.E. Tumor repopulation during radiotherapy Quantitation in two xenografted human tumors . Int J Radiat Oncol Biol Phys. 39:1997;803-808.
51. Gerber H.-P., Dixit V., Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem. 273:1998;13313-13316.
52. Lammering G., Lin P.S., Contessa J.N., et al. Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells. Int J Radiat Oncol Biol Phys. 51:2001;775-784.
53. Lammering G., Hewit T.H., Hawkins W.T., et al. Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization. J Natl Cancer Inst. 93:2001;921-929.
54. Huang S.M., Bock J.M., Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 59:1999;1935-1940.
55. Bonner J.A., Raisch K.P., Trummell H.Q., et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol. 18:2000;47S-53S.
56. Nasu S., Ang K.K., Fan Z., et al. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys. 51:2001;474-477.
57. Harari P.M., Huang S.M. Modulation of molecular targets to enhance radiation. Clin Cancer Res. 6:2000;323-325.